BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 954 filers reported holding BAXTER INTL INC in Q1 2014. The put-call ratio across all filers is 0.58 and the average weighting 0.5%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $98,300,000 | -17.1% | 1,530,430 | +0.1% | 0.02% | +5.0% |
| Q1 2022 | $118,593,000 | -9.8% | 1,529,448 | -0.1% | 0.02% | -4.8% |
| Q4 2021 | $131,419,000 | -37.9% | 1,530,977 | -41.8% | 0.02% | -41.7% |
| Q3 2021 | $211,562,000 | -74.0% | 2,630,392 | -74.0% | 0.04% | -73.9% |
| Q2 2021 | $813,230,000 | -0.0% | 10,102,239 | +4.8% | 0.14% | -8.0% |
| Q1 2021 | $813,359,000 | +8.8% | 9,643,813 | +3.5% | 0.15% | +4.2% |
| Q4 2020 | $747,519,000 | +77.2% | 9,316,035 | +77.6% | 0.14% | +56.5% |
| Q3 2020 | $421,855,000 | +425.3% | 5,245,643 | +149.2% | 0.09% | +318.2% |
| Q4 2015 | $80,312,000 | -76.6% | 2,105,157 | -79.9% | 0.02% | -78.2% |
| Q3 2015 | $343,867,000 | -63.5% | 10,467,784 | -22.2% | 0.10% | -60.4% |
| Q2 2015 | $941,452,000 | -5.2% | 13,462,784 | -7.1% | 0.26% | -4.9% |
| Q1 2015 | $992,756,000 | +0.4% | 14,492,784 | +7.4% | 0.27% | 0.0% |
| Q4 2014 | $988,886,000 | -1.4% | 13,492,784 | -3.4% | 0.27% | -5.0% |
| Q3 2014 | $1,002,827,000 | +9.9% | 13,972,784 | +10.7% | 0.28% | +12.4% |
| Q2 2014 | $912,627,000 | -6.5% | 12,622,784 | -4.9% | 0.25% | -9.7% |
| Q1 2014 | $976,309,000 | -28.9% | 13,268,679 | -32.8% | 0.28% | -28.0% |
| Q4 2013 | $1,373,368,000 | -35.2% | 19,746,484 | -38.8% | 0.39% | -40.0% |
| Q3 2013 | $2,118,611,000 | -9.5% | 32,251,655 | -4.6% | 0.64% | -15.3% |
| Q2 2013 | $2,341,344,000 | – | 33,800,255 | – | 0.76% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |